Catalent passes baton to activist investor Elliott after 2023 earnings disappoint fkansteiner Wed, 08/30/2023 – 09:26 More: Catalent passes baton to activist investor Elliott after 2023 earnings disappoint Source: fierce
read moreThe therapy involves treating individuals with atherosclerotic cardiovascular disease More: Novartis reveals vital Leqvio data Source: News
read moreFunding will progress the manufacture of oligonucleotide therapeutics alongside machine learning More: Intellegens and CPI awarded Innovate UK grant Source: News
read morePfizer, BioNTech seek administrative review of 2 Moderna patents at heart of mRNA vaccine litigation fkansteiner Tue, 08/29/2023 – 15:38 More: Pfizer, BioNTech seek administrative review of 2 Moderna patents at heart of mRNA vaccine litigation Source: fierce
read moreFierce 50 spotlight: Social Impact category chair Andrea Park aellison Tue, 08/29/2023 – 11:14 More: Fierce 50 spotlight: Social Impact category chair Andrea Park Source: fierce
read moreBristol Myers Squibb’s Reblozyl, chasing $4B sales target, wins key FDA label expansion zbecker Tue, 08/29/2023 – 11:02 More: Bristol Myers Squibb's Reblozyl, chasing B sales target, wins key FDA label expansion Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals